MARKET

AMPE

AMPE

AMPIO PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9597
+0.0454
+4.97%
Opening 11:31 12/02 EST
OPEN
0.9800
PREV CLOSE
0.9143
HIGH
1.000
LOW
0.9228
VOLUME
3.26M
TURNOVER
--
52 WEEK HIGH
1.390
52 WEEK LOW
0.3100
MARKET CAP
177.60M
P/E (TTM)
-12.8819
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ampio Pharmaceuticals to complete enrollment in early-stage with inhaled Ampion in COVID-19 patients
Ampio Pharmaceuticals ([[AMPE]] +6.1%) says that its Phase I trial of inhaled Ampion (AP-014) in COVID-19 patients proceeded to full open enrollment following clearance by the Safety Monitoring Committee ((SMC)), which found Ampion to
Seekingalpha · 49m ago
Ampio Announces Phase 1 Study For Inhaled Advances To Complete Enrollment Of COVID-19 Patients With Respiratory Distress
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress ENGLEWOOD, Colo., Dec. 2, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc.
Benzinga · 2h ago
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
PR Newswire · 2h ago
Do Options Traders Know Something About Ampio (AMPE) Stock We Don't?
Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.
Zacks · 1d ago
Ampio updates on Phase 1 study with inhaled Ampion in COVID-19 patients
Ampio ([[AMPE]] +0.2%) provides following update on clinical trials.Phase I trial of inhaled Ampion (AP-014), the third of three initial safety groups of patients have completed five days of treatment and three
Seekingalpha · 11/25 14:50
UPDATE: Ampio Says Third Of Three Initial Safety Groups Of Patients Have Completed 4 Days Of Treatment, Three Days Of Follow Up For Phase 1 Ampion Clinical Trial
Ampio Updates Regulatory and Clinical Trial Events ENGLEWOOD, Colo., Nov. 25, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of
Benzinga · 11/25 14:16
Ampio Updates Regulatory, Clinical Trial Events
Ampio Updates Regulatory and Clinical Trial Events ENGLEWOOD, Colo., Nov. 25, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of
Benzinga · 11/25 14:15
Amipo Pharma Reports Third Group In Phase 1 Inhaled Ampion Study Being Treated Following Clearance By Safety Monitoring Committee
Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the third group in the
Benzinga · 11/17 14:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMPE. Analyze the recent business situations of AMPIO PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMPE stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 20.94M
% Owned: 11.32%
Shares Outstanding: 185.06M
TypeInstitutionsShares
Increased
13
1.36M
New
15
8.35M
Decreased
18
7.05M
Sold Out
15
1.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.06%
Pharmaceuticals & Medical Research
+0.58%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Macaluso
Chief Financial Officer/Treasurer/Secretary
Daniel Stokely
Chief Operating Officer
Holli Cherevka
Director
David Bar-Or
Independent Director
Philip Coelho
Independent Director
Richard Giles
Independent Director
David Stevens
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMPE
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ampio Pharmaceuticals Inc stock information, including AMEX:AMPE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMPE stock methods without spending real money on the virtual paper trading platform.